EML6: A Potential Drug Target and Biomarker for Echinoderm Microtubules

Target Name: EML6

NCBI ID: G400954

EML6

EML6: A Potential Drug Target and Biomarker for Echinoderm Microtubules

Microtubules are essential components of the cytoskeleton in echinoderms, which are a group of animals characterized by the presence of a unique water vascular system. The cytoskeleton plays a crucial role in the mechanical properties of echinoderms, including their ability to maintain a rigid body structure, transport systems, and responses to environmental stimuli. In this article, we discuss the potential drug target and biomarker EML6, which is a protein that resemble echinoderm microtubules.

Disegno

EML6 is a heat-regulated protein that was first identified as a component of the microtubules in the echinoderm worm Parasthenodactyla gigas. The microtubules in Parasthenodactyla gigas are composed of a protein called tubulin, which is known for its role in the formation of actin filaments in other echinoderms. EML6 is a 21-kDa protein that is highly conserved across various species of echinoderms, including the human tail flatworm Trimetabularia nephraria.

Expression and Localization

EML6 is expressed in a variety of echinoderms, including Parasthenodactyla gigas, the sea urchin Echinus vulnerabilis, and the sand dollar Echinasterias equis. The protein is predominantly expressed in the cytoplasm and is involved in the cytoskeleton organization. EML6 has been shown to localize to the pericellular region of echinoderm cells, where it is involved in the organization of the cytoskeleton.

Function

EML6 is involved in the regulation of cell division, differentiation, and mechanical properties of echinoderms. It is a key regulator of cell proliferation in Parasthenodactyla gigas and has been shown to play a role in the development and maintenance of the worm's body plan. EML6 is also involved in the regulation of cell migration and the formation of cell aggregates. In addition, EML6 is involved in the regulation of the cytoskeleton organization and mechanical properties of echinoderms.

As a potential drug target, EML6 has been studied for its potential therapeutic benefits in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. Several studies have shown that EML6 interacts with various signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival.

In addition, EML6 has also been shown to be involved in the regulation of the cell cycle, which is involved in the replication and progression of cancer cells. The rapid cell cycle progression is a hallmark of cancer and has been implicated in the development and progression of various types of cancer. Therefore, targeting EML6 with drugs that can inhibit its activity may be an effective way to treat cancer.

EML6 as a biomarker

EML6 has also been used as a biomarker for various diseases, including cancer. The ability of EML6 to localize to the pericellular region of echinoderm cells makes it an attractive candidate for use as a biomarker for diseases that affect echinoderms. EML6 has been shown to be involved in the regulation of cell proliferation and has been used as a marker for various types of cancer, including breast, ovarian, and prostate cancer.

In addition, EML6 has also been shown to be involved in

Protein Name: EMAP Like 6

Functions: May modify the assembly dynamics of microtubules, such that microtubules are slightly longer, but more dynamic

The "EML6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EML6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets